Johnson & Johnson CIO Jim Swanson announced at the Reuters Momentum AI event that AI has halved the time required to generate new drug development leads. The technology effectively screens promising chemical compounds rather than discovering drugs outright.

AI has already accelerated development for two specific compounds in oncology and immunology. J&J also integrates AI across medical device segments to reduce heart mapping times for arrhythmia procedures.

AI improves precision for knee and hip replacement surgeries. The technology streamlines regulatory document preparation, reducing clinical trial report times from hundreds of hours to minutes. These initiatives support J&Jā€™s strategy to offset upcoming patent expirations for top-selling drugs like Stelara.